University of North Carolina Hospitals Micrographic Surgery and Dermatologic Oncology

Topics

• Hidradenitis Suppurativa and Treatments 106
• Cutaneous Melanoma Detection and Management 66
• Reconstructive Facial Surgery Techniques 22
• Melanoma and MAPK Pathways 18
• Nonmelanoma Skin Cancer Studies 16
• T-cell and B-cell Immunology 16
• Autoimmune Bullous Skin Diseases 11
• Sphingolipid Metabolism and Signaling 9
• Immunotherapy and Immune Responses 7
• Skin Protection and Aging 7
• Drug-Induced Adverse Reactions 6
• Genital Health and Disease 6

Most cited

1. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.

   Lancet (London, England) · 2024 · 149 citations · Christopher Sayed

2. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.

   Journal of the American Academy of Dermatology · 2022 · 187 citations · Christopher Sayed

3. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.

   Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · 56 citations · Christopher Sayed

4. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.

   JAMA dermatology · 2021 · 144 citations · Christopher Sayed

5. Genetic Variants Associated With Hidradenitis Suppurativa.

   JAMA dermatology · 2023 · 64 citations · Nancy Thomas, Christopher Sayed

6. Target molecules for future hidradenitis suppurativa treatment.